Infectious disease modeller and leader of the Infection Epidemiology and Policy Analytics Group at the @KirbyInstitute.
Joined August 2021
- Tweets21
- Following30
- Followers60
- Likes1
Deborah Cromer retweeted
Strong link between early viral load reduction by anti-COVID treatments and clinical efficacy.
Helps rapidly progress better treatments.
Bravo, great work by Khoury, Davenport and team. @IAP_Sydney @TheDohertyInst @KirbyInstitute @viralvaxlab medrxiv.org/content/10.1101/…
Deborah Cromer retweeted
Neutralizing #antibody titers elicited by either ancestral or bivalent #COVID19 #vaccine boosters are predicted to increase protection against severe disease due to #SARSCoV2 variants. @DebCro @IAP_Sydney @KirbyInstitute
nature.com/articles/s41591-0…
Deborah Cromer retweeted
Do you like your covid-19 vaccines to give you a good dose of neutralising antibodies? You should because we've shown they correlate not only with protection from symptomatic but also severe disease! Another great collab with @DebCro nature.com/articles/s41467-0…
Deborah Cromer retweeted
What role do T cells play in vaccine-induced immunity to SARS-CoV-2? Discussed here: go.nature.com/3y9zhIV
@sarah_sasson
@DebCro
@TricckyLab
@profstephenkent
@viralvaxlab
@EJohnWherry
#COVID-19 #vaccines #SARSCoV2
Deborah Cromer retweeted
Commentary in @Nature on our analysis of dosing and timing of antibody therapies for COVID-19
Pre-print at medRxiv doi.org/10.1101/2022.03.21.2…
Deborah Cromer retweeted
Check out Dr Deborah Cromer's interview with @normanswan on today's @RadioNational Health Report discussing our analysis of antibody treatments for COVID-19
abc.net.au/radionational/pro…
@KirbyInstitute @markpoliz @AndelLestcourt @NSkoetz @Monash_SPHPM
Are monoclonals, convalescent plasma or hyperimmune Ig an effective treatment strategy for COVID-19? Check out the latest analysis. Researchers at @KirbyInstitute in collab with our @erica_m_wood @ZoeMcquilten Khai Li Chai and others show timing matters! medrxiv.org/content/10.1101/…
